IBM Watson pioneer Dr. John E. Kelly III shares his perspective on AI adoption barriers, data quality, and the future of AI-enabled neurological...
Discover how the new McDonald criteria use imaging biomarkers such as the Central Vein Sign (CVS) to make earlier, more accurate MS diagnosis
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and...
The imaging clinical trials industry continues to grow in the face of unique challenges! To help you keep up, we’ve put together the top trends to...
Learn how QMENTA simplifies central vein detection in Multiple Sclerosis. Our solution automates protocol adherence, sequence recognition, and white...
QMENTA's neuroimaging platform enables Parkinson's disease research through AI-powered MRI and PET biomarker analysis — including iron accumulation,...
Discover how the Central Vein Sign (CVS) — with 95% sensitivity and 92% specificity — is transforming MS diagnosis and how QMENTA powered the CAVS-MS...